Which has stronger earnings and valuation, SCPS or VINC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scopus BioPharma N/A N/A -$11.61M N/A N/A Vincerx Pharma N/A N/A -$40.16M -$5.31 N/A

Is SCPS or VINC more profitable?

Scopus BioPharma's return on equity of 0.00% beat Vincerx Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Scopus BioPharma N/A N/A N/A Vincerx Pharma N/A -248.33% -132.73%

Which has higher valuation and earnings, ARDS or SCPS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aridis Pharmaceuticals N/A N/A -$30.37M $0.09 N/A Scopus BioPharma N/A N/A -$11.61M N/A N/A

Is ARDS or SCPS more profitable?

Company Net Margins Return on Equity Return on Assets Aridis Pharmaceuticals N/A N/A N/A Scopus BioPharma N/A N/A N/A

Which has better valuation and earnings, CLVR or SCPS?

Scopus BioPharma has lower revenue, but higher earnings than Clever Leaves. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Clever Leaves $17.42M 0.00 -$17.90M -$12.36 N/A Scopus BioPharma N/A N/A -$11.61M N/A N/A

Is CLVR or SCPS more profitable?

Company Net Margins Return on Equity Return on Assets Clever Leaves N/A N/A N/A Scopus BioPharma N/A N/A N/A

Which has stronger earnings and valuation, SCPS or SMFL?

Scopus BioPharma has higher earnings, but lower revenue than Smart for Life. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scopus BioPharma N/A N/A -$11.61M N/A N/A Smart for Life $11.11M 0.00 -$22.68M -$14.48 N/A

Is SCPS or SMFL more profitable?

Company Net Margins Return on Equity Return on Assets Scopus BioPharma N/A N/A N/A Smart for Life N/A N/A N/A

Which has stronger valuation and earnings, VRPX or SCPS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virpax Pharmaceuticals N/A N/A -$15.19M -$123.25 N/A Scopus BioPharma N/A N/A -$11.61M N/A N/A

Is VRPX or SCPS more profitable?

Scopus BioPharma's return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Virpax Pharmaceuticals N/A -1,554.34% -338.29% Scopus BioPharma N/A N/A N/A

Scopus BioPharma (SCPS) Competitors

$0.0005 0.00 (0.00%)

As of 07/2/2026

Compare

SCPS vs. VINC, ARDS, CLVR, SMFL, and VRPX

Should you buy Scopus BioPharma stock or one of its competitors? MarketBeat compares Scopus BioPharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Scopus BioPharma include Vincerx Pharma (VINC), Aridis Pharmaceuticals (ARDS), Clever Leaves (CLVR), Smart for Life (SMFL), and Virpax Pharmaceuticals (VRPX). These companies are all part of the "pharmaceutical products" industry.

How does Scopus BioPharma compare to Vincerx Pharma?

Scopus BioPharma (NASDAQ:SCPS) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

44.0% of Vincerx Pharma shares are owned by institutional investors. 5.1% of Scopus BioPharma shares are owned by insiders. Comparatively, 15.6% of Vincerx Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Vincerx Pharma'saverage media sentiment score.

Company	Overall Sentiment
Scopus BioPharma	Neutral
Vincerx Pharma	Neutral

Scopus BioPharma's return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scopus BioPharma	N/A	N/A	N/A
Vincerx Pharma	N/A	-248.33%	-132.73%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scopus BioPharma	N/A	N/A	-$11.61M	N/A	N/A
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A

Scopus BioPharma has a beta of -0.25, indicating that its share price is 125% less volatile than the broader market. Comparatively, Vincerx Pharma has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market.

Summary

Scopus BioPharma and Vincerx Pharma tied by winning 3 of the 6 factors compared between the two stocks.

How does Scopus BioPharma compare to Aridis Pharmaceuticals?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.

Aridis Pharmaceuticals has a beta of 44.97, meaning that its stock price is 4,397% more volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.25, meaning that its stock price is 125% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aridis Pharmaceuticals	N/A	N/A	-$30.37M	$0.09	N/A
Scopus BioPharma	N/A	N/A	-$11.61M	N/A	N/A

In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company	Overall Sentiment
Aridis Pharmaceuticals	Neutral
Scopus BioPharma	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Aridis Pharmaceuticals	N/A	N/A	N/A
Scopus BioPharma	N/A	N/A	N/A

9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. 5.5% of Aridis Pharmaceuticals shares are owned by company insiders. Comparatively, 5.1% of Scopus BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Aridis Pharmaceuticals beats Scopus BioPharma on 3 of the 4 factors compared between the two stocks.

How does Scopus BioPharma compare to Clever Leaves?

Clever Leaves (NASDAQ:CLVR) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.

Company	Net Margins	Return on Equity	Return on Assets
Clever Leaves	N/A	N/A	N/A
Scopus BioPharma	N/A	N/A	N/A

Scopus BioPharma has lower revenue, but higher earnings than Clever Leaves.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clever Leaves	$17.42M	0.00	-$17.90M	-$12.36	N/A
Scopus BioPharma	N/A	N/A	-$11.61M	N/A	N/A

6.9% of Clever Leaves shares are held by institutional investors. 8.2% of Clever Leaves shares are held by insiders. Comparatively, 5.1% of Scopus BioPharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Clever Leaves has a beta of 3816.13, suggesting that its share price is 381,513% more volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.25, suggesting that its share price is 125% less volatile than the broader market.

In the previous week, Clever Leaves' average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company	Overall Sentiment
Clever Leaves	Neutral
Scopus BioPharma	Neutral

Summary

Clever Leaves beats Scopus BioPharma on 4 of the 5 factors compared between the two stocks.

How does Scopus BioPharma compare to Smart for Life?

Scopus BioPharma (NASDAQ:SCPS) and Smart for Life (NASDAQ:SMFL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings.

Scopus BioPharma has a beta of -0.25, suggesting that its share price is 125% less volatile than the broader market. Comparatively, Smart for Life has a beta of 15.06, suggesting that its share price is 1,406% more volatile than the broader market.

In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score.

Company	Overall Sentiment
Scopus BioPharma	Neutral
Smart for Life	Neutral

Scopus BioPharma has higher earnings, but lower revenue than Smart for Life.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scopus BioPharma	N/A	N/A	-$11.61M	N/A	N/A
Smart for Life	$11.11M	0.00	-$22.68M	-$14.48	N/A

Company	Net Margins	Return on Equity	Return on Assets
Scopus BioPharma	N/A	N/A	N/A
Smart for Life	N/A	N/A	N/A

28.4% of Smart for Life shares are held by institutional investors. 5.1% of Scopus BioPharma shares are held by insiders. Comparatively, 31.7% of Smart for Life shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Smart for Life beats Scopus BioPharma on 4 of the 5 factors compared between the two stocks.

How does Scopus BioPharma compare to Virpax Pharmaceuticals?

Virpax Pharmaceuticals (NASDAQ:VRPX) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virpax Pharmaceuticals	N/A	N/A	-$15.19M	-$123.25	N/A
Scopus BioPharma	N/A	N/A	-$11.61M	N/A	N/A

Scopus BioPharma's return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virpax Pharmaceuticals	N/A	-1,554.34%	-338.29%
Scopus BioPharma	N/A	N/A	N/A

Virpax Pharmaceuticals has a beta of -16.52, meaning that its stock price is 1,752% less volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.25, meaning that its stock price is 125% less volatile than the broader market.

32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. 3.7% of Virpax Pharmaceuticals shares are owned by insiders. Comparatively, 5.1% of Scopus BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Virpax Pharmaceuticals' average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company	Overall Sentiment
Virpax Pharmaceuticals	Neutral
Scopus BioPharma	Neutral

Summary

Scopus BioPharma beats Virpax Pharmaceuticals on 5 of the 6 factors compared between the two stocks.

Get Scopus BioPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SCPS vs. The Competition

Export

Metric	Scopus BioPharma	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$21K	$791.45M	$7.17B	$12.48B
Dividend Yield	N/A	4.84%	2.66%	6.52%
P/E Ratio	N/A	1.66	28.02	24.70
Price / Sales	N/A	127.53	540.72	98.05
Price / Cash	N/A	20.06	49.26	57.09
Price / Book	N/A	8.17	10.96	6.46
Net Income	-$11.61M	-$3.71M	$3.57B	$337.01M
7 Day Performance	N/A	2.59%	2.12%	1.69%
1 Month Performance	N/A	4.41%	5.25%	3.81%
1 Year Performance	N/A	49.43%	33.29%	23.90%

Scopus BioPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SCPS Scopus BioPharma	N/A	$0.00 flat	N/A	N/A	$21K	N/A	N/A	9
VINC Vincerx Pharma	N/A	$0.01 flat	N/A	-66.7%	$66K	N/A	N/A	60	High Trading Volume
ARDS Aridis Pharmaceuticals	N/A	$0.00 -86.7%	N/A	N/A	$21K	N/A	0.00	30	Gap Down
CLVR Clever Leaves	N/A	N/A	N/A	N/A	$18K	$17.42M	N/A	560
SMFL Smart for Life	N/A	$0.00 flat	N/A	N/A	$14K	$11.11M	N/A	110	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SCPS) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Scopus BioPharma (SCPS) Competitors

SCPS vs. VINC, ARDS, CLVR, SMFL, and VRPX

How does Scopus BioPharma compare to Vincerx Pharma?

Summary

How does Scopus BioPharma compare to Aridis Pharmaceuticals?

Summary

How does Scopus BioPharma compare to Clever Leaves?

Summary

How does Scopus BioPharma compare to Smart for Life?

Summary

How does Scopus BioPharma compare to Virpax Pharmaceuticals?

Summary

Media Sentiment Over Time

SCPS vs. The Competition

Scopus BioPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Scopus BioPharma (SCPS) Competitors

SCPS vs. VINC, ARDS, CLVR, SMFL, and VRPX

How does Scopus BioPharma compare to Vincerx Pharma?

Do insiders and institutionals believe in SCPS or VINC?

Does the media prefer SCPS or VINC?

Is SCPS or VINC more profitable?

Which has stronger earnings and valuation, SCPS or VINC?

Which has more volatility and risk, SCPS or VINC?

Summary

How does Scopus BioPharma compare to Aridis Pharmaceuticals?

Which has more volatility & risk, ARDS or SCPS?

Which has higher valuation and earnings, ARDS or SCPS?

Does the media refer more to ARDS or SCPS?

Is ARDS or SCPS more profitable?

Do institutionals and insiders believe in ARDS or SCPS?

Summary

How does Scopus BioPharma compare to Clever Leaves?

Is CLVR or SCPS more profitable?

Which has better valuation and earnings, CLVR or SCPS?

Do insiders & institutionals hold more shares of CLVR or SCPS?

Which has more volatility and risk, CLVR or SCPS?

Does the media prefer CLVR or SCPS?

Summary

How does Scopus BioPharma compare to Smart for Life?

Which has more risk & volatility, SCPS or SMFL?

Does the media favor SCPS or SMFL?

Which has stronger earnings and valuation, SCPS or SMFL?

Is SCPS or SMFL more profitable?

Do insiders and institutionals believe in SCPS or SMFL?

Summary

How does Scopus BioPharma compare to Virpax Pharmaceuticals?

Which has stronger valuation and earnings, VRPX or SCPS?

Is VRPX or SCPS more profitable?

Which has more risk & volatility, VRPX or SCPS?

Do insiders and institutionals hold more shares of VRPX or SCPS?

Does the media refer more to VRPX or SCPS?

Summary

Media Sentiment Over Time

SCPS vs. The Competition

Scopus BioPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools